These data provide a rationale for specific targeting of this molecular pathway in diseases genetically associated with the IL6R locus, rather than non-specific blockade of IL-6 signalling which brings with it an increased risk of infection that might not be acceptable in the context of T1D in children. The gene discussed is IL6R; the disease is type 1 diabetes mellitus.